Akston Biosciences Corporation, a leader in advancing biologics for animal health, has announced a strategic partnership with Energesis Pharmaceuticals, Inc., a biopharmaceutical company specializing in obesity and metabolic diseases. This collaboration aims to develop an innovative treatment for obesity in companion animals by harnessing their natural ability to burn more calories and increase energy expenditure.

The partnership focuses on leveraging cutting-edge research in brown adipose tissue (BAT) biology, which has shown promise in generating heat, burning calories, and reducing overall body fat while preserving muscle mass. This approach is expected to promote healthy weight loss in pets without the adverse effects commonly associated with appetite-suppressing drugs.

As part of the agreement, Akston Biosciences has secured an exclusive option to license Energesis’ BAT recruitment therapy for companion animals. Akston will also serve as the Contract Development and Manufacturing Organization (CDMO) to further develop and produce this therapy at its facility in Beverly, Massachusetts.

“This partnership exemplifies Akston’s dedication to advancing the AVMA One Health Initiative, reflecting our commitment to translational medicine,” said Todd Zion, PhD, President & CEO of Akston Biosciences. “By integrating innovations across human and veterinary sciences, we aim to contribute to a healthier, more interconnected world where the well-being of people, animals, and the environment are seamlessly linked.”

The collaboration with Energesis marks Akston’s second major in-licensing deal in recent months, following its agreement with Purdue University to co-develop an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy for treating cancer in dogs. These strategic moves are part of Akston’s broader effort to expand its veterinary pipeline, which includes therapies for chronic pain, atopic dermatitis, and cancer in companion animals, all developed using its proprietary Ambifect® platform.

Akston’s recent deals also underscore its commitment to supporting the commercial development of pioneering veterinary health technologies, particularly those created by academic researchers and start-ups. These innovative sources often face challenges in securing venture capital and support from larger veterinary pharmaceutical companies.

“Energesis and Akston share a passion for innovation as we work to develop new, differentiated products to treat obesity in pets,” added Dr. Brian Freeman, CEO of Energesis. “Brown adipose tissue recruitment therapy represents a major advancement in obesity treatment. Unlike current approaches that suppress appetite and cause muscle loss, our therapy enhances energy use, promoting healthy weight loss without rebound. We are thrilled to partner with Akston to bring this technology to the veterinary space.”

The partnership between Akston Biosciences and Energesis Pharmaceuticals aims to address the significant need for effective obesity treatments in companion animals, while also paving the way for potential future applications in human medicine.